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ABSTRAK 
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Ejen antikoagulan dan antifibrinolitik yang sedia ada, dilaporkan mempunyai kesan 
sampingan yang boleh mengancam nyawa. Oleh itu pencarian ejen baru dari sumber 
semulajadi sangat diperlukan pada masa kini. Mikania cordata, juga dikenali sebagai 
selaput tunggul telah digunakan secara tradisional oleh golongan tua untuk merawat 
pelbagai jenis jangkitan dan penyakit. Tujuan kajian ini adalah untuk mengkaji kesan M. 
cordata ke atas aktiviti pembekuan darah dan menganalisis sebatian bioaktif yang ada di 
dalam ekstrak daun yang mungkin mempunyai kesan ke atas aktiviti pembekukan darah. 
Aktiviti pembekuan darah dikaji secara in vitro menggunakan ujian masa prothrombin 
(PT), pengaktifan separa masa tromboplastin (APTT) dan masa thrombin (TT) yang diukur 
mengunakan plasma yang mengandungi antikoagulan sitrat daripada penderma sukarela 
yang sihat. Plasma dicampurkan dengan ekstrak daun mengikut kepekatan yang berbeza 
(0.78, 1.56, 3.13, 6.25, 12.50 dan 25.00 mg/mL) dan keputusan  menunjukkan bahawa 
masa APTT dan TT berpanjangan berbanding dengan kontrol. Namun begitu, ujian PT 
menunjukkan keputusan aktiviti prokoagulan pada kepekatan 3.13mg/mL dan aktiviti 
antikoagulan pada kepekatan 12.5 dan 25.0 mg/mL. Keputusan analisis kromatografi gas - 
spektrometri jisim menunjukkan kehadiran sebatian bioaktif dalam ekstrak akueus daun M. 
cordata seperti asid caffeic, bis (trimethylsilyl) ester O (trimethylsilyl) - asid malic; 
2,3,4,5- tetrakis-O (trimethylsilyl) - arabinose; 1,2,3,5- tetrakis-O (trimethylsilyl) - 
arabinofuranose; octakis (trimethylsilyl) melibiose; dan octakis (trimethylsilyl) - maltosa 
yang menyumbang kepada aktiviti antikoagulan. Sebagai kesimpulan, penemuan ini 
menunjukkan bahawa M. cordata berpotensi menjadi produk antikoagulan berasaskan 
tumbuhan untuk keperluan klinikal masa hadapan.  
ABSTRACT 
xiii 
 
Existing anticoagulants and antifibrinolytic agents have been reported to have life-
threatening side effects. Therefore, a search for novel agents of natural origin is demanded 
nowadays.  Mikania cordata also known as ‘selaput tunggul’ was traditionally used by 
folks to treat various infections and diseases. In this study the aimed was to investigate the 
effect of M. cordata in blood coagulation activities and to analyse the bioactive 
compounds in the leaves extract which might have significant effects on coagulation 
activities of the blood. The in vitro blood coagulation activities such as prothrombin time 
(PT), activated partial thromboplastin time (APTT) and thrombin time (TT) assay were 
measured on citrated plasma from healthy volunteer donors. The plasma was spiked with 
different concentration of aqueous leaves extract (0.78, 1.56, 3.13, 6.25, 12.50 and 25.00 
mg/mL) and the results showed that the prolongation of APTT and TT in concentration-
dependent manner (p<0.01). However in the PT assay, the results showed procoagulant 
activities at concentration 3.13 mg/mL and anticoagulant activities at concentration 12.5 
and 25.0 mg/mL. The result of gas chromatography mass spectrometry (GCMS) analysis 
showed the presence of bioactive compounds in aqueous extract of M. cordata such as 
caffeic acids, bis (trimethylsilyl) ester O–(trimethylsilyl)- malic acid; 2,3,4,5- tetrakis-O- 
(trimethylsilyl)- arabinose; 1,2,3,5- tetrakis-O- (trimethylsilyl)- arabinofuranose; octakis 
(trimethylsilyl) melibiose; and octakis (trimethylsilyl)- maltose are known contributing 
compounds for anticoagulant effects. As a conclusion, these findings suggest that M. 
cordata may provide a potential plant based anticoagulant products for future clinical use.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Blood coagulation 
Basic coagulation is a major defence mechanism (Lee et al., 2013) and the blood flow 
must be regulated in order to avoid bleeding by balancing the bleeding (haemorrhage) 
and clotting (thrombosis) process. Haemostasis is defined as process of blood clotting, 
which is followed by a process of dissolving or lysing the clotted blood (Harmening, 
2001). Many inherited or acquired conditions can disturb its function. The components 
involved in haemostasis are vasoconstriction process, the platelet adhesion, activation 
and aggregation, activation of blood coagulation cascade and fibrinolytic system 
(Hoffbrand et al., 2006).  
 
Vasoconstriction is the process of reducing the diameter of blood vessels to reduce the 
blood flow at the site of injury and minimise the loss of blood at injury site. Then the 
platelet adhesion, activation and aggregation take place simultaneously with activation 
of blood coagulation cascade. Platelet activation will lead to the platelet accumulation at 
the injury sites and prevent the blood loss. The blood coagulation will continue by 
production of fibrin to entrap the blood at the injury sites and form blood clots (Ciesla, 
2012, Hoffbrand et al., 2006).   
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Coagulation is divided into two major systems which are primary and secondary 
haemostasis systems. The primary haemostatic system consists of vasoconstriction and 
platelet function meanwhile the secondary haemostatic system involved in activation of 
coagulation cascade proteins, platelet phospholipids, and substrates in a series of 
delicately balanced enzymatic reactions that lead up to in fibrin formation and reinforce 
the formation of platelet plug until the healing process complete. The conversion of the 
soluble fibrinogen into insoluble fibrin clot is accompanied by the thrombin’s action. 
Thrombin is a powerful coagulant factor that formed from prothrombin, a precursor of 
circulating protein. The process then followed by dissolution of platelet plug and the 
fibrin clot meshwork is achieved by fibrinolysis process (Ciesla, 2012).  
 
Blood coagulation system is a enzymatic cascade that initiated the response upon the 
tissue damage (Hoffbrand et al., 2006, Karim et al., 2013). An immediate response of 
vasoconstriction of the injured vessels is responsible for an initial slowing the blood 
flow to the area of injury. Cascade of circulating precursor protein are the coagulation 
factors enzymes which is culminates in the generation of the thrombin and convert the 
soluble plasma fibrinogen into fibrin. Fibrin will entrap the platelet aggregates at the 
sites of vascular injury and converts the unstable primary platelets plugs to firm, 
definitive and stable haemostatic plug (Harmening, 2001, Hoffbrand et al., 2006). 
Thrombin also responsible for the feedback activation of other blood coagulation factors 
and it is considered as important factors in blood coagulation (Guglielmone et al., 
2001).  
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Majority of blood coagulation factors involved are pro-enzyme, which is needed to be 
activated sequentially, one after another in the blood coagulation cascade (Hoffbrand et 
al., 2006). Blood coagulation system involves three pathways which are extrinsic, 
intrinsic and common pathways. Although it has been traditional and useful for in vitro 
laboratory testing to divide the coagulation system into extrinsic and intrinsic pathways, 
such a division actually does not occur in vivo. This is because the tissue factor - factor 
VIIa complex is a potent activator for both factor IX and factor X. Both intrinsic and 
extrinsic pathways require initiation that leads to subsequent activation of various 
coagulation factors in cascading, waterfall or domino effects and both share common 
pathways (Harmening, 2001).  
 
1.1.1 Extrinsic pathway 
The principal of initiating pathway in vivo blood coagulation is the extrinsic pathway, 
which involve the components of blood and vascular elements. The crucial component 
is the tissue factor which an intrinsic membrane protein composed of a single 
polypeptide chain. This protein functions as a cofactor to factor VIII in intrinsic system, 
and to factor V in the final common pathway. Tissue factor inhibitor (TFPI) is a protein 
that in association with factor Xa which is inhibits the tissue factor - factor VII complex 
(Colman et al., 2006). The extrinsic pathway is initiated with the release of tissue 
thromboplastin that has been expressed after the damage to a blood vessel. Factor VII, 
tissue thromboplastin and calcium are later formed as a complex which converts factor 
X into Xa. Factor Xa with the help of factor V then converts the prothrombin to 
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thrombin. Furthermore the thrombin causes the conversion of fibrinogen to fibrin. This 
entire process normally takes between 10 and 15 seconds to complete (Ciesla, 2012).  
 
Figure 1.1: Blood coagulation cascade  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from Essential Haematology, 6th Edition, 2011, © A. V. Hoffbrand & P.A.H. Moss)  
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1.1.2 Intrinsic pathway 
Intrinsic pathway also known as contact pathway is initiated upon the contact of blood 
to the negatively charged foreign substance such as collagen, endothelial surface, or 
phospholipids. Intrinsic pathway consist of factors I, II, V, VIII,  IX, and XII 
(Hoffbrand et al., 2006). The vascular trauma induces the changes that initiate a 
cascading sequence of contact activation and results in the activation of factor IX by a 
novel dimeric serine protease factor Xia, providing a pathway independent of factor VII 
for blood coagulation. However, an important difference exists between these two 
pathways in the clotting cascade whereas the activation of factor IX by XIa requires 
only in the presence of ionised calcium. The activation of factor IX by VIIa requires the 
protein cofactor, tissue factor, calcium that embedded in a lipid bilayer cell membrane 
(Ciesla, 2012, Colman et al., 2006).   
 
The role of the contact system proteins in initiation of intrinsic pathway of coagulation 
in haemostasis is questionable because only a deficiency of factor XI is associated with 
a haemorrhagic tendency. These proteins participate instead in the initiation of the 
inflammatory response, angiogenesis, complement activation, fibrinolysis, and kinin 
formation. The previous studies show that kininogen is an anticoagulant protein in vivo. 
The mechanism may be due to the inhibiting the binding of low concentrations of 
thrombin to platelet GP Ib/IX (Colman et al., 2006).  
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According to Ciesla (2012), the factor XII auto activates to factor XIIa in the presence 
of the protein prekallikrein meanwhile the activation of factor XI to factor Xia requires 
the presence of another protein which is cofactor of HMWK. The factor XIa activates 
the factor IX to factor IXa, which is then, converts the factor X to factor Xa in the 
presence of factor VIIIa and platelet phospholipid factor PF3. Calcium is requires in 
rapid activation of factor X. The reaction then enters the common pathway of blood 
coagulation cascade (Ciesla, 2012).  
 
1.1.3 Common pathway 
The common pathway is the point at which the intrinsic and extrinsic pathways merge 
and combined together, where the factors I, II, V and X are measured. Prothrombin time 
(PT) and activated partial thromboplastin time (APTT) do not detect the quantitative or 
qualitative of platelet disorders or factor XIII deficiency. Factor XIII also known as the 
fibrin stabilizing factor, is responsible for stabilizing a soluble fibrin monomer into 
insoluble fibrin clot. A patient with factor XIII deficiency cannot stabilize the clot and 
lead to the bleeding to occur (Bennett et al., 2007, Hoffbrand et al., 2006). 
 
1.1.4 Role of thrombin in fibrinogen  
The activation of plasma fibrinogen by a protease enzyme, thrombin will results in a 
stable fibrin clot and visible proof of fibrin formation. Thrombin also participates in 
factor XIII-XIIIa activation, which occurs when thrombin cleaves a peptide bond from 
each of the two alpha chains. It combined with the calcium ions and caused the 
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inactivation of the factor XIII. This process enables the factor XIII to dissociate to 
factor XIIIa. If the thrombin are allowed to circulates in its active form (factor Ia), 
uncontrolled clotting would occurred. Therefore the thrombin circulates in its inactive 
form, prothrombin (factor II). Thrombin cleaves fibrinogen (factor I), which results in a 
stable fibrin monomer and fibrinogen peptides A and B. These initial monomers 
polymerise end-to-end because of the hydrogen bonding (Ciesla, 2012, Hoffbrand et al., 
2006). 
 
According to the Ciesla B. (2012), the fibrin formation can occurs in three phases 
including proteolysis, polymerisation and stabilisation. Proteolysis occurs when 
protease enzyme thrombin cleaves the fibrinogen and resulting in a fibrin monomer, A 
and B fibrinopeptides. Polymerisation occurs spontaneously when fibrin monomers line 
up end-to-end because of hydrogen bonding meanwhile the stabilisation occurs when 
the factor XIIIa covalently links with the fibrin monomers into fibrin polymers and 
forming an insoluble fibrin clot. This clot will enclosed the injury sites and heal the 
wound (Ciesla, 2012, Harmening, 2001).    
 
1.1.5 Haemostasis screening assays 
In normal screening test of coagulation pathways to detect the blood coagulation 
disorder, PT, APTT and thrombin time (TT) are used as measurements. According to 
Bennett et al. (2007), the PT assay measuring the extrinsic (tissue factor) and common 
pathways meanwhile the APTT measures the intrinsic and common pathways. The PT 
and APTT assays are useful to distinguish between the effects of the test agents 
including leaves extract, fruit extract and other natural compounds on the intrinsic and 
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extrinsic pathways. The TT assay are important in evaluating disorders of thrombin, 
haemostasis as well as the presence of oral anticoagulant heparin (Brown, 1988).  
 
1.1.5.1 PT assay 
The PT assay has two purposes which are; to screen for acquired or inherited as well as 
deficiencies in the extrinsic and common pathways of blood coagulation cascade. As we 
know, each pathway has specific coagulation factors such as factor VII, X, II 
(prothrombin), I (fibrinogen) and V involve in extrinsic pathway and factor X and V 
involve in common pathway (Hoffbrand et al., 2006).  
 
The PT assay is affected by decreased level of extrinsic factors. Since the prothrombin, 
factor VII and X that measured by PT assay are vitamin K-dependent protein, therefore 
PT assay are useful for detecting vitamin K deficiency from any causes including 
warfarin therapy, liver disease or malnutrition. The PT assay also frequently used to 
follow oral anticoagulant therapy such as warfarin which is inhibiting the factors X, IX, 
VII, and II (Dey and Bhakta, 2012). However, the PT assay does not measure the factor 
XIII activity or other factors of the intrinsic pathway.    
 
The PT is performed by mixing the citrated plasma with the commercial tissue factor, 
thromboplastin and calcium which resulting the activation of the factors VII, X, V, 
fibrinogen and prothrombin. Thromboplastin which is a commercial factor that derived 
from animal tissue or recombinant methods. Tissue factor in the preparation of 
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thromboplastin will binds to the factor VII in citrated plasma and initiate the 
coagulation process. The clotting time is measured in seconds using instruments with 
photo-optical or mechanical endpoints that detect the formation of fibrin in plasma. The 
normal values range for PT is 10 – 15 seconds depending on normal range of the 
laboratory (Bennett et al., 2007, Brown, 1988, Dey and Bhakta, 2012, Hoffbrand et al., 
2006).   
 
In general the PT assay is more sensitive in detecting the low levels of factors VII and X 
as compared to low levels of prothrombin, fibrinogen or factor V. In particular the 
different thromboplastin reagents may exhibits sensitivities of variable to these 
deficiencies factors. The PT assay are reported less affected by heparin when compare 
to APTT assay (Bennett et al., 2007). Shortened the PT values may result from poor 
quality of venipuncture, deficiency or inhibition of one or more of the following factors: 
VII, X, V, II and fibrinogen, liver disease, warfarin therapy, disseminated intravascular 
coagulopathy (DIC) disease or cold activation of sample which is in vitro activation 
from factor XII activation by factor VII that occurs if the citrated plasma sample is 
stored at cold temperatures above freezing for several hours (Bennett et al., 2007, 
Brown, 1988, Hoffbrand et al., 2006).       
 
1.1.5.2 APTT assay 
The APTT assay is one of the most common assays in the clinical coagulation 
laboratory. This assay is useful for screening the acquired or inherited deficiencies of 
intrinsic pathway, for detecting the lupus anticoagulant and for monitoring heparin 
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therapy. The APTT assay measures the factors VIII, IX, XI and XII in addition to 
fibrinogen, prothrombin, and factor X and V. This assay is affected by the decreased 
levels of intrinsic pathways components as well as decreased levels of common 
pathway components; however factors VII and XIII are not measured (Hoffbrand et al., 
2006, Harmening, 2001, Bennett et al., 2007).  
  
In general, the APPT is performed by adding the citrated patient plasma to the APTT 
reagent which is contact activator and its need preincubation period to initiate the 
activation of factors in intrinsic pathway. This will involves the activation of factors XII 
and XI in the presence of cofactors, prekallikrein and high-molecular-weight kininogen. 
The activated factor XI is then converts the factor IX to activated factor IX. After that, 
the calcium is then added to the preincubation mixture which results in the factors 
IXa/VIII activation of factor X and then the activation of prothrombin into thrombin 
followed up by conversion of fibrinogen into soluble fibrin that polymerises into stable 
fibrin. The formation stable fibrin is the endpoint as the clotting time for APTT assay 
which detected by using instruments with photo-optical and mechanical (Bennett et al., 
2007). The normal values range for APTT assay is approximately 30 – 40 seconds 
depends on the laboratory normal values ranges.  
 
Prolongation of clotting time in the APTT assay suggest a possibility of the disturbance 
in the complex coagulation cascade that involve wider range of coagulation factors 
which indicated the deficiency or inhibition of one or more of the following factors: 
VII, X, V, II and fibrinogen (Karim et al., 2013). The most common cause of disorder 
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are Hemophilia A (factor VIII) and Christmas disease also known as Hemophilia B 
(factor IX). The APTT assay also will be affected in the presence of circulation 
inhibitors such as antithrombin, protein C and protein S towards the inhibition of the 
calcium ion or phospholipids action and coagulation factors (Laffan and Manning, 
2010). Prolongation of APTT and PT also can be seen with the low levels of fibrinogen 
(Karim et al., 2013).  
  
 
1.1.5.3 TT assay 
 
The TT assay is performed by adding the thrombin that usually harvested from bovine 
or human origin, purified and lyophilised into the citrated plasma either with or without 
added calcium. This assay measures the amount and quantity of fibrinogen and the rate 
of conversion of fibrinogen into stable fibrin (Goodnight and Hathaway, 2001). 
Thrombin is a protease protein produced in the activation of plasma prothrombin. 
Thrombin function is to cleave the fibrinopeptides A and B from α and β polypeptide 
monomer of circulating fibrinogen. Upon the cleavage, the individual fibrinogen 
molecules polymerise and forming insoluble fibrin, the protein in the visible clot 
(Corriveau and Fritsma, 1988).  
 
 
In general, TT is performed by adding citrated plasma as a source of fibrinogen and if 
the fibrinogen is available in the plasma, quantitatively and qualitatively, a fibrin clot is 
established once the standard concentration of thrombin has been added into the plasma. 
The reference range is 11 to 15 seconds depends on the laboratory environment and 
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analyzer. A prolonged TT assay may indicate the deficiency of normal fibrinogen 
usually <100 mg/dL, as normally seen in the patients with congenital 
hypofibrinogenemia or afibrinogenemia. The TT assay may rarely be prolonged in 
conditions with abnormally high levels of fibrinogen (inflammation) or more 
commonly, qualitatively abnormal fibrinogen (hereditary dysfibrinogenemia, cirrhosis, 
hepatocellular carcinoma, and newborn infants) (Bennett et al., 2007).  
 
 
Substances those interfering with the thrombin-induced fibrinogen conversion to a 
fibrin are associated with a prolonged TT including heparin, antithrombin antibodies 
after exposure to bovine thrombin, proteolytic products of fibrin, and fibrinogen, 
procainamide-induced anticoagulant, systemic amyloidosis and abnormal serum 
proteins. Combinations of these mechanisms producing an increased TT are seen in 
renal disease and DIC (Corriveau and Fritsma, 1988, Goodnight and Hathaway, 2001). 
 
 
1.1.6 Blood coagulation disorders  
Platelet and blood coagulation factors are the two important components that involve in 
the formation of the blood clot. Any deficiencies and defect involves in blood 
coagulation factors will cause the bleeding disorders. According to Hoffbrand et al. 
(2006), bleeding disorder can be acquired or inherited. Inherited blood disorder such as 
hemophilia A (deficiency of factor VIII), hemophilia B (deficiency of factor IX) and 
von Willebrand’s disease (deficiency of vW factor). Meanwhile, the acquired disorders 
are liver disease, vitamin K deficiencies, drugs such as warfarin, DIC and others. 
13 
 
In blood coagulation disorders such as hemophilia A, any injuries will cause the 
bleeding disorder such as prolonged the bleeding after dental extractions, surgery, 
giving birth, spontaneous haematuria and haemorrhage. These conditions can lead to 
death in severe conditions. Therefore the patients need to be treated with some drugs 
such as with antifibrinolytic (tranexamic acid for mild bleeding) or procoagulant 
treatment to improve the efficacy of the coagulation cascade (Hoffbrand et al., 2006, 
Rang et al., 2007).  
 
Blood clots also known as thrombus can develop in the blood vessels and circulatory 
system because of imbalance between clotting and bleeding will lead to blockage of 
vascular. This condition can be serious and responsible to health threatening results. 
Thrombosis are divided into two type which are arterial thrombus which arise and form 
in the arteries, meanwhile the venous thrombus are the thrombus that form in the veins 
of blood vessels (Jain et al., 2014).  There are various diseases that arising from the 
blood clots problem such as deep vein thrombosis, pulmonary embolism, 
atherosclerosis, diabetic complications, cerebral vascular accident (CVA) and 
myocardial infarction which are the major life threatening disease lead to morbidity and 
mortality (Jain et al., 2014, Sherwani et al., 2013). 
 
Thrombolysis process is a complex mechanism that interacts with the clot components 
and surrounding plasma which involve the component of plasminogen, fibrin, 
plasminogen activator and plasmin. Antithrombolytic agents are used in order to treat 
the diseases and dissolve the blood clots in the blood vessels. Anticoagulant therapy 
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attempts to impede thrombus formation in individuals who have predisposing factors for 
a clot formation or who are predisposed by virtue of a medical event without the threat 
of morbidity or mortality from hemorrhage. Warfarin is an oral anticoagulant, which 
means it must be ingested. It was discovered accidentally at the University of Wisconsin 
in 1939 after a farmer found that his cattle were haemorrhaging to death for no apparent 
reason. The cattle grazed in a field of sweet clover, which contains dicumarol (actually, 
bishydroxycoumarin) causing the cattle to bleed (Ciesla, 2012). 
 
Aspirin and heparin are markedly effective in treating the patient with thrombolytic 
disease by activating the lysis and preventing the reocclusion. There are also several 
compounds of coumadin including indanedione, dicumarol, and warfarin. Dicumarol 
works too slowly in the patients and indanedione has many side effects. Warfarin, or 4-
oxycoumarin, is the most commonly used oral anticoagulant. Warfarin works by 
inhibiting the y-carboxylation step of clotting and the vitamin K-dependent factors 
(Ciesla, 2012, Karim et al., 2013). Therefore all the anticoagulant and antifibrinolytic 
have their own deleterious side effect that need to be replaces by others natural product 
which have no side effects. 
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1.2 Mikania cordata 
1.2.1 Structure 
Mikania cordata plant is a smooth vine, climber shrub that widely grow in Malaysia 
(Ab. Patar and Yahaya, 2012), have serrated leaves, many white flowers and known as 
common obnoxious weed to Bangladesh (Nayeem et al., 2011). M. cordata is a fast 
growing, perennial vine, creeping or twining, and branches stems. The leaves are 
slender and long-petioled, ovate heart-shaped or deltoid-ovoid with 4 -10 centimeters 
long, with pointed tip, rounded heart-shaped or truncate base and toothed margins. The 
matured leaves, the stem and the branches are easily form the roots when the leaves 
come contact with the soil (Bulbul et al., 2013). The heads of plant are 4-flowered with 
cylindrical, 6-9 millimeter long and borne in compound inflorescences. Achenes are 
smooth, glandular and linear-oblong with 2.5-3 millimeters long. The pappus of this 
plant is composed of one series, 40-45 bristles, about 4mm long, whitish at first and 
salmon coloured (reddish) afterwards. Maybe distinguished by the following 
characteristics: 40 to 45 reddish pappus bristles, corollas white and heads 7 to 7.5 mm 
long.  
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Figure 1.2: Mikania cordata 
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1.2.2 Classification 
 Kingdom: Plantae 
 Subkingdom: Tracheobionta 
 Superdivision: Spermatophyta 
 Division:  Magnoliophyta 
 Class:  Magnoliopsida 
 Subclass:  Asteridae 
 Order: Asterales 
 Family: Asteraceae 
 Genus: Mikania 
 Species: Mikania cordata 
(Adapted from NRCS, United States Department of Agriculture)  
 
Mikania cordata (Burm.f) B.L. Robinson, are locally known as ‘akar lupang’, “selaput 
tunggul’ and ‘ulam tikus’ among Malaysia and in Indonesia known as ‘sembung 
rambat’. This plant also known as Taralata, Asamlata, Chinese creeper and Germalata 
(Nayeem et al., 2011, Bulbul et al., 2013), Dubainna lota (Rashid et al., 2012), Refugee 
(Biswas et al., 2011) is a traditional plant that commonly used among folks.  
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1.2.3 Geographical distribution 
M. cordata are found throughout of tropical regions in India, Bangladesh (Paul et al., 
2000), Philippines, Malaysia (Ab. Patar and Yahaya, 2012), Brazil, Africa and  South 
America including Argentina, Paraguay, and Uruguay (Bulbul et al., 2013).  
 
1.2.4 Active compounds 
Acetic acid can be found in herbs leaves such as M. cordata leaves. The previous study 
has found that acetic acid compound was the third most compound composition of total 
of M. cordata leaves (6.27%). Furthermore, a lot of chemical compounds were reported 
such as hydroquinone, stigmasterol, deoxyspergualin, glycerin and squalene (Ab. Patar 
and Yahaya, 2012).  In Mikania micrantha, the main compounds were sesquiterpenoids, 
flavonoids, coumarins, diterpenes, pytosterols, polyphenols, terpenoids, mikanolide, 
miscandenin derivatives, sequiterpenes lactones and halohydrocarbon (Gasparetto et al., 
2010, Li et al., 2013, Ahmed et al., 2001). 
 
 
The previous study showed that M. cordata leaves extract have the compounds of α-
cubene (21.3%), spathulenol (3%), γ-curcumene (6.3%), β-pinene (4.1%), α-cedrene 
(4.9%), copaene (4.1%), caryophyllene oxide (10.1%) and α-bisabolol (6.6%) 
(Aguinaldo et al., 2003a). In others study using flower oils extract of M. cordata 
reported that various bioactive compounds such as such as β-pinene (14.9%), 
zingiberene (6%), α-bergamotene (5.6%), β-caryophyllene (5.6%), γ-curcumene 
(11.7%) and α-cubebene (12.4%) (Chowdhury et al., 2007, Aguinaldo et al., 2003b).    
19 
 
Moreover, the mikamicranolide, dihydromikanolide, 2 – cubebene, γ – elemene, 2 – 
copaene, deoxymikanolide and mikanokryptin were reported in  M. micrantha using 
aerial parts. In M. micrantha was reported the presence of 3,4-di-O-caffeoylquinic acid 
n-butyl ester, eupalitin, eupafolin, luteolin,  and 3,5-di-O-caffeoylquinic acid n-butyl 
ester (Herz et al., 1967, Huang et al., 2009).  
 
1.2.5 Medicinal values 
The leaves of M. cordata has been proven to treat several illness such as antiulcer 
activity (Paul et al., 2000), analgesic effect (Ahmed et al., 2001), effect on nervous 
system (Bhattacharya et al., 1988), antibacterial (Sekendar A.Shaiful et al., 2011). The 
Tonchongya Tribe in Bandarban District of Bangladesh has used the leaves of M. 
cordata (Burm.f) and Chromolaena odorata (L.) King & H.Rob. by crushing together 
and applied to wounds and cuts to stop the bleeding instantly (Rashid et al., 2012). The 
crashed leaves are used to stop bleeding from cuts and wounds, against jaundice, septic 
sore and snake bite among Bangladesh’s folks (Nayeem et al., 2011, Biswas et al., 
2011) and traditionally used to stop the bleeding among Malaysian’s folks (Ab. Patar & 
Yahaya, 2012). 
 
Among Bangladesh’s folk, the infusion and decoction of leaves are used for colds, 
influenza, fever and bronchitis in children. Besides that, the decoction of flower also is 
used for coughs and diabetes. The whole plants are rich sources of vitamin A, B and C 
and also used for fish poisoning. It is easily to get this plant because it is a very rapidly 
growing perennial vine and wildly grow on the ground. In the previous study Ab. Patar 
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and Yahaya (2012) shown that the M. cordata leaves consist of bioactive compounds 
which is known as acetic acid. Acetic acid was the third most abundant in this plants 
and might have a potential effect in blood coagulation system. This was proven by 
Victor Fernandez-Duenas et al. (2008) which reported that the acetic acid has clinical 
significant in blood coagulation study as a procoagulant because it reduced the bleeding 
time in mice. However, because of the problem in sample size of the subjects, the study 
was inconclusive in the present time (Ab. Patar and Yahaya, 2012). Considering the 
effect of M. cordata leaves, it is crucial to look into this plant in term of bioactive 
compound as well as the blood coagulation activities. Therefore in this study, the main 
objective was to investigate the blood coagulation compounds of the Malaysian M. 
cordata leaves that lead to blood coagulation activities of human plasma in vitro.  
 
1.3 Rationale of study 
Anticoagulants and antifibrinolytics play vital roles in the clinical medicine as agents 
for prevention and treatment of thromboembolic and blood coagulation disorder. 
Anticoagulants including heparin and warfarin meanwhile, antifibrinolytic including 
tranexamic acids have been used widely for more than five decades. Although the 
efficacy of these drugs still remains undisputed, the deleterious life-threatening side 
effects have been well documented and led to high morbidity and mortality rate (Jain et 
al., 2014, Manicam et al., 2010).  
 
Considering the life-threatening side effects, the novel anticoagulant must be developed 
to overcome the morbidity and mortality rate in patients. Since the production of 
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developing this novel coagulant and anticoagulant is costly; therefore a cheaper yet 
effective alternative would be a great welcome in clinical settings. This limitations has 
led to the exploitation of plants as an alternative method to overcome the side effects, 
since the plants is considered as a reliable source for new invention of a novel coagulant 
and anticoagulant agents (Jain et al., 2014, Felix-Silva et al., 2014, Guglielmone et al., 
2001). Hence, more studies pertaining to the use of plants as therapeutic agents should 
be emphasised, especially those related to blood coagulation activities.  
 
1.4 Objectives  
1.4.1 General objective 
 To investigate the effects of Malaysian Mikania cordata leaves extracts on human 
blood coagulation activities in vitro.  
 
1.4.2 Specific objectives 
 To study the effects of in vitro blood coagulation activities in different concentration 
of aqueous extract of Malaysian Mikania cordata leaves using prothrombin time 
(PT), activated partial thromboplastin time (APTT) and thrombin time (TT) assays. 
 To determine the composition that involves in blood coagulation activities of 
Mikania cordata leaves in aqueous and ethanolic extracts by using Gas 
Chromatographic Mass Spectrometry (GCMS). 
 
22 
 
1.5 Hypothesis 
HA : Malaysian Mikania cordata leaves enhance the blood coagulation activities  
HO : Malaysian Mikania cordata leaves have no effects on blood coagulation activities 
 
 
1.6 Expected outcome  
 There are blood coagulation activities in aqueous extract of Mikania cordata 
using PT, APTT and TT Assay in vitro. This finding is expected to benefits in 
clinical treatment as the nature coagulant, either procoagulant or anticoagulant. 
If the plant acts as procoagulant, it can be used as antifibrinolytic for treatment 
of thromboembolic, treat the wound healing and stop the bleeding. If the plant 
acts as anticoagulant, it can be used for treatment of blood coagulation disorder.   
 There are compositions that enhance the blood coagulation activities in Mikania 
cordata that can be identified in aqueous and ethanol extracts by using GCMS. 
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The overview of the research is visualised in the Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Flow chart of study 
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CHAPTER 2 
MATERIALS AND METHOD 
 
2.1 Materials  
2.1.1 Preparation of 0.9 % normal saline (0.9% NaCl) 
0.9 mg of sodium chloride powder (NaCl) (Sigma-Aldrich, United States) was weighted 
and dissolved in volumetric flask (1 ml) that containing 1000 ml of distilled water 
(dH2O) to produce 0.9% of normal saline. The solution was mixed until all the powder 
dissolved. Then, the 0.9% normal saline solution was aliquots in small Schott’s bottle 
for storage at room temperature until further use.  
 
2.1.2 Preparation of STA Reagents (Diagnostica Stago, S.A.S France) 
2.1.2.1 Preparation of STA - Coag Control N+P reagent 
1 ml of distilled water (dH2O) was added in both STA - Coag Control N vial and STA - 
Coag Control P vial (Diagnostica Stago, S.A.S France). The reconstituted materials 
were allowed to stand at room temperature (18 – 25 °C) for 30 minutes. After that, the 
reagents were mixed well by swirling the vial without creating any bubbles before use. 
 
 
 
